Related Experiment Videos

Monoclonal antibody ONS-M21 recognizes integrin alpha3 in gliomas and medulloblastomas

H Kishima1, K Shimizu, K Tamura

  • 1Department of Neurosurgery, Osaka University Medical School, Suita, Japan.

British Journal of Cancer
|January 15, 1999
PubMed

Insights

A new antibody, ONS-M21, targets a protein on glioma and medulloblastoma cells. This protein, integrin alpha3, correlates with tumor grade, suggesting ONS-M21

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Immunology

Background:

  • Gliomas and medulloblastomas are primary brain tumors.
  • Identifying specific biomarkers for these tumors is crucial for diagnosis and treatment.

Purpose of the Study:

  • To identify and characterize a novel antigen recognized by the monoclonal antibody ONS-M21.
  • To investigate the potential diagnostic utility of ONS-M21 in brain tumors.

Main Methods:

  • Purification and identification of the ONS-M21 target antigen using antibody-binding affinity chromatography.
  • Sequence homology analysis to identify the antigen.
  • Quantitative analysis of integrin alpha3 mRNA levels in tumor specimens.

Main Results:

  • The ONS-M21 antibody recognizes a 140-kDa protein expressed on glioma and medulloblastoma cells, but not normal brain tissue.
  • The identified antigen shares sequence homology with integrin alpha3.
  • Integrin alpha3 mRNA levels correlate with the malignancy grade of gliomas and medulloblastomas.

Conclusions:

  • The ONS-M21 antibody targets integrin alpha3, a protein overexpressed in malignant brain tumors.
  • Integrin alpha3 shows potential as a diagnostic marker for gliomas and medulloblastomas.
  • The ONS-M21 antibody may aid in the diagnosis of these brain cancers.

Related Concept Videos